Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

Ipsita Pal, PhD, Yu Ri Kim, MD, Sohani Das Sharma, PhD, Prabhjot S. Mundi, MD, Andre M. Grilo, PhD, Luke E Berchowitz, PhD, Mingzhao Zhu, PhD, Hull G. Kenneth, PhD, Daniel Romo, PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 4067.

https://doi.org/10.1182/blood-2019-131816

Published: 2019

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Ipsita Pal, PhD, Sohani Das Sharma, PhD, Andre M. Grilo, PhD, Prabhjot S. Mundi, MD, Luigi Scotto, PhD, Abdullah Mahmood Ali, PhD, Luke E Berchowitz, PhD, Siddhartha Mukherjee, MD PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 2864.

https://doi.org/10.1182/blood-2019-129528

Published: 2019

Journal Articles

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas, MD, John Kuruvilla, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Francesca Montanari, MD, Kerry J Savage, BSc, MD MSc, Hager Elgedawe, Diego Villa, MD, Michael Crump, MD, Joseph M Connors, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2018-99-117251

Published: 2018

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2018-99-116605

Published: 2018

Journal Articles

Silencing Oncogene Translation Using Pateamine a Analogues As a Novel Therapeutic Strategy for c-Myc Driven Lymphoma

Yu Ri Kim, MD, Ipsita Pal, PhD, Mark R Lipstein, PhD, Mingzhao Zhu, Hull Kenneth, Daniel Romo, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 4111.

https://doi.org/10.1182/blood.V130.Suppl_1.4111.4111

Published: 2017

Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 4037.

https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037

Published: 2017

Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 2809.

https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809

Published: 2017

Journal Articles

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Enrica Marchi, MD, PhD, Emily Lichtenstein, RN, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Celeste Rojas, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 1515.

https://doi.org/10.1182/blood.V130.Suppl_1.1515.1515

Published: 2017

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

Journal Articles

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

Lorenzo Falchi, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Emily Lichtenstein, RN, Karen Khan, BSN, Lawrence H. Schwartz, MD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 2999.

https://doi.org/10.1182/blood.V128.22.2999.2999

Published: 2016

Journal Articles

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Matko Kalac, MD PhD, Cristine Candland, RN, Lisa Wallace, RN, Elizabeth Gentner, RN, Shreya Shah, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Suzanne Lentzsch, MD PhD, Owen A. O'Connor, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 5834.

https://doi.org/10.1182/blood.V128.22.5834.5834

Published: 2016

Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 1824.

https://doi.org/10.1182/blood.V128.22.1824.1824

Published: 2016

Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 1280.

https://doi.org/10.1182/blood.V126.23.1280.1280

Published: 2015

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Luigi Scotto, PhD, Xavier Jirau-Serrano, BS, Kelly Zullo, MS, Michael Mangone, PhD, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3703.

https://doi.org/10.1182/blood.V126.23.3703.3703

Published: 2015

Journal Articles

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O'Connor, MD, Ian W. Flinn, MD PhD, Manish R. Patel, MD, Timothy S. Fenske, MD, Changchun Deng, MD PhD, Danielle M. Brander, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John G Kuhn, Pharm.D., Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Howard A. Burris, III, MD

Blood (2015) 126 (23): 4154.

https://doi.org/10.1182/blood.V126.23.4154.4154

Published: 2015

Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 586.

https://doi.org/10.1182/blood.V126.23.586.586

Published: 2015

Journal Articles

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Yun Hao, Nicholas P. Tatonetti, PhD, Michael Mangone, PhD, Shirong Li, PhD, Suzanne Lentzsch, Ronald B. Realubit, PhD, Charles Karan, Jr., PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 593.

https://doi.org/10.1182/blood.V126.23.593.593

Published: 2015

NARROW

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Silencing Oncogene Translation Using Pateamine a Analogues As a Novel Therapeutic Strategy for c-Myc Driven Lymphoma

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only